Abstract
Antagonizing vasodilation has been considered one of the potential mechanisms underlying the pathophysiology of preeclampsia. Phosphodiesterases hydrolyze cGMP, interfering with the action of nitric oxide on vascular smooth muscle, thus causing vasoconstriction. We hypothesize that the phosphodiesterases in maternal plasma, phosphodiesterase-5 in particular, may be linked to clinical manifestations in preeclampsia syndrome.
Copyright © 2017 Elsevier Ltd. All rights reserved.
MeSH terms
-
Arginine / metabolism
-
Cytokines / metabolism
-
Endothelium, Vascular / physiopathology
-
Epoprostenol / metabolism
-
Female
-
Humans
-
Hydrolysis
-
Inflammation
-
Muscle, Smooth, Vascular / enzymology
-
Neovascularization, Pathologic
-
Nitric Oxide / metabolism
-
Phosphodiesterase Inhibitors / pharmacology*
-
Phosphoric Diester Hydrolases / metabolism*
-
Pre-Eclampsia / enzymology*
-
Pregnancy
-
Renin-Angiotensin System
-
Signal Transduction / drug effects
-
Thromboxanes / metabolism
-
Vasodilation / physiology
-
Vasodilator Agents / pharmacology
Substances
-
Cytokines
-
Phosphodiesterase Inhibitors
-
Thromboxanes
-
Vasodilator Agents
-
Nitric Oxide
-
Arginine
-
Epoprostenol
-
Phosphoric Diester Hydrolases